Ambea AB/Skr AMBEA
1D1W1MYTD1Y5YMAX
Capital at risk
About Ambea AB
Ambea AB is a company operating within the healthcare and social services industry, primarily offering care services in the Nordic region. The company provides elderly care, disabled care, and psychosocial support services, focusing on high-quality living and well-being for its users. Founded in 1996, Ambea is headquartered in Stockholm, Sweden, and operates through several brands, including Vardaga and Nytida, ensuring a broad service coverage across Sweden, Norway, and Denmark. The company is strategically positioned through its strong regional presence and an extensive network of facilities and professionals, enabling efficient service delivery and high standards of care.
- Ticker
- Skr AMBEA
- Sector
- Health
- Primary listing
- XSTO
- Employees
- 41,000
- Headquarters
- Solna, Sweden
- Website
- www.ambea.se
Ambea AB Metrics
BasicAdvanced
kr 13B
17.27
kr 9.54
0.67
kr 2.65
1.61%
Price and volume
Market cap
kr 13B
Beta
0.67
52-week high
kr 176.40
52-week low
kr 112.70
Average daily volume
365K
Dividend rate
kr 2.65
Financial strength
Current ratio
0.407
Quick ratio
0.363
Long term debt to equity
2.073
Total debt to equity
2.571
Dividend payout ratio (TTM)
26.94%
Interest coverage (TTM)
2.83%
Profitability
EBITDA (TTM)
1,648
Gross margin (TTM)
27.89%
Net profit margin (TTM)
4.63%
Operating margin (TTM)
8.44%
Effective tax rate (TTM)
21.38%
Revenue per employee (TTM)
kr 410,000
Management effectiveness
Return on assets (TTM)
4.23%
Return on equity (TTM)
15.50%
Valuation
Price to earnings (TTM)
17.272
Price to revenue (TTM)
0.798
Price to book
2.58
Price to tangible book (TTM)
-3.4
Price to free cash flow (TTM)
6.169
Free cash flow yield (TTM)
16.21%
Free cash flow per share (TTM)
26.716
Dividend yield (TTM)
1.61%
Forward dividend yield
1.61%
Growth
Revenue change (TTM)
13.87%
Earnings per share change (TTM)
28.00%
3-year revenue growth (CAGR)
9.45%
3-year earnings per share growth (CAGR)
38.48%
3-year dividend per share growth (CAGR)
28.46%
Bulls say / Bears say
Ambea’s second-quarter performance showed improving operating leverage: sales rose 7 per cent year on year, while adjusted EBITA increased 28 per cent and the margin widened to 9.0 per cent from 7.6 per cent. Earnings per share almost doubled to SEK 2.13. (Ambea, MarketScreener)
The proposed Humana acquisition could strengthen Ambea’s scale and operating platform across the Nordic region. Management says identified cost synergies are worth about SEK 120 million and could help the combined business return to its 9.5 per cent EBITDA margin target by the end of 2028. (StockAnalysis, Ambea)
Humana adds execution and regulatory risk at an important point in Ambea’s expansion. The transaction is complex, and delivering the promised synergies will depend on integrating the businesses without disrupting care operations. (Yahoo Finance, StockAnalysis)
Recent expansion is not uniformly accretive to margins. Validia’s child-welfare start-up and integration costs are weighing on profitability, while further unit openings in the second half are expected to carry costs before occupancy builds. (Yahoo Finance, Inderes)
Municipal budget pressure could limit occupancy and pricing, particularly in Norway. Ambea says financially constrained municipalities are changing their purchasing behaviour, while seasonal staffing costs and the need to recruit thousands of care professionals add further pressure to margins. (Yahoo Finance, Exa)
Data summarised monthly by Lightyear AI. Last updated on 15 Sept 2026.
Upcoming events
No upcoming events
Funds containing Ambea AB
AllEURGBPUSD
Fund name | Fund size | Skr AMBEA weighting |
|---|---|---|
iShares Ageing Population€AGED | €822M | 0.10% |
Xtrackers MSCI Europe Small Cap€DX2J | €3.2B | 0.08% |
Xtrackers MSCI Europe Small Cap£XXSC | £2.8B | 0.08% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.